Low-Dose Versus Therapeutic Anticoagulation in Patients on Extracorporeal Membrane Oxygenation: A Pilot Randomized Trial. Issue 7 (July 2019)

• Record Type: Journal Article
• Authors: Aubron, Cécile; McQuilten, Zoe; Bailey, Michael; Board, Jasmin; Buhr, Heidi; Cartwright, Bruce; Dennis, Mark; Hodgson, Carol; Forrest, Paul; McIlroy, David; Murphy, Deirdre; Murray, Lynne; Pellegrino, Vincent; Pilcher, David; Sheldrake, Jayne; Tran, Huyen; Vallance, Shirley; Cooper, D. James
• Is Part Of: Critical care medicine. Volume 47:Issue 7(2019)
• Publication Date: 2019-07
• Subjects: activated partial thromboplastin time -- anti-Xa -- bleeding -- extracorporeal membrane oxygenation -- hemostasis -- thrombosis; Critical care medicine -- Periodicals; Soins intensifs -- Périodiques; 616.028
• DOI: 10.1097/CCM.0000000000003780
• Languages: English
• ISSNs: 0090-3493

Abstract

Abstract : Objectives: To determine whether randomization of patients undergoing extracorporeal membrane oxygenation to either therapeutic or a low-dose anticoagulation protocol results in a difference in activated partial thromboplastin time and anti-Xa. Design: Randomized, controlled, unblinded study. Setting: Two ICUs of two university hospitals. Patients: Patients admitted to the ICU, who required extracorporeal membrane oxygenation (venovenous or venoarterial) and who did not have a preexisting indication for therapeutic anticoagulation. Interventions: Therapeutic anticoagulation with heparin (target activated partial thromboplastin time between 50 and 70 s) or lower dose heparin (up to 12, 000 U/24 hr aiming for activated partial thromboplastin time < 45 s). Measurements and Main Results: Thirty-two patients were randomized into two study groups that were not significantly different in demographics and extracorporeal membrane oxygenation characteristics. There was a significant difference in the daily geometric mean heparin dose (11, 742 U [95% CI, 8, 601–16, 031 U] vs 20, 710 U [95% CI, 15, 343–27, 954 U]; p = 0.004), daily geometric mean activated partial thromboplastin time (48.1 s [95% CI, 43.5–53.2 s] vs 55.5 s [95% CI, 50.4–61.2 s]; p = 0.04), and daily geometric mean anti-Xa (0.11 international units/mL [95% CI, 0.07–0.18] vs 0.27 [95% CI, 0.17–0.42]; p = 0.01). We found similar results when considering only venovenous extracorporeal membrane oxygenation episodes; however, no difference in daily geometric mean activated partial thromboplastin time between groups when considering only venoarterial extracorporeal membrane oxygenation episodes. Conclusions: Allocating patients on extracorporeal membrane oxygenation to two different anticoagulation protocols led to a significant difference in mean daily activated partial thromboplastin time and anti-Xa levels between groups. When considering subgroups analyses, these results were consistent in patients on venovenous extracorporeal membrane oxygenation. Our results support the feasibility of a larger trial in patients undergoing venovenous extracorporeal membrane oxygenation to compare different anticoagulation protocols; however, this study does not provide evidence on the optimal anticoagulation protocol for patients undergoing extracorporeal membrane oxygenation. Abstract : Supplemental Digital Content is available in the text.